Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 148; pp. 105 - 112
• Main Authors: Christopoulos, P., Kirchner, M., Roeper, J., Saalfeld, F., Janning, M., Bozorgmehr, F., Magios, N., Kazdal, D., Volckmar, A.L., Brückner, L.M., Bochtler, T., Kriegsmann, M., Endris, V., Penzel, R., Kriegsmann, K., Eichhorn, M., Herth, F.J.F., Heussel, C.P., El Shafie, R.A., Schneider, M.A., Muley, T., Meister, M., Faehling, M., Fischer, J.R., Heukamp, L., Schirmacher, P., Bischoff, H., Wermke, M., Loges, S., Griesinger, F., Stenzinger, A., Thomas, M.
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01-10-2020
• Subjects: Brain metastases; EGFR+ NSCLC; Overall survival; TP53 mutation; Treatment failure; Tyrosine kinase inhibitor; EGFR+ NSCLC; Treatment failure; Brain metastases; Overall survival; Tyrosine kinase inhibitor; TP53 mutation
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2020.08.007

•EGFR variant, TP53 and brain status together predict survival in EGFR+ NSCLC (ENS).•Co-mutations beyond TP53 are rare and their clinical significance remains unclear.•The ENS is a practical and reproducible baseline risk stratification of EGFR+ NSCLC.
Panel-based next-generation sequencing (NGS) is increasingly used for the diagnosis of EGFR-mutated non-small-cell lung cancer (NSCLC) and could improve risk assessment in combination with clinical parameters.
To this end, we retrospectively analyzed the outcome of 400 tyrosine kinase inhibitor (TKI)-treated EGFR+ NSCLC patients with validation of results in an independent cohort (n = 130).
EGFR alterations other than exon 19 deletions (non-del19), TP53 co-mutations, and brain metastases at baseline showed independent associations of similar strengths with progression-free (PFS hazard ratios [HR] 2.1–2.3) and overall survival (OS HR 1.7–2.2), in combination defining patient subgroups with distinct outcome (EGFR+NSCLC risk Score, "ENS", p < 0.001). Co-mutations beyond TP53 were rarely detected by our multigene panel (<5%) and not associated with clinical endpoints. Smoking did not affect outcome independently, but was associated with non-del19 EGFR mutations (p < 0.05) and comorbidities (p < 0.001). Laboratory parameters, like the blood lymphocyte-to-neutrophil ratio and serum LDH, correlated with the metastatic pattern (p < 0.01), but had no independent prognostic value. Reduced ECOG performance status (PS) was associated with comorbidities (p < 0.05) and shorter OS (p < 0.05), but preserved TKI efficacy. Non-adenocarcinoma histology was also associated with shorter OS (p < 0.05), but rare (2–3 %). The ECOG PS and non-adenocarcinoma histology could not be validated in our independent cohort, and did not increase the range of prognostication alongside the ENS.
EGFR variant, TP53 status and brain metastases predict TKI efficacy and survival in EGFR+ NSCLC irrespective of other currently available parameters ("ENS"). Together, they constitute a practical and reproducible approach for risk stratification of newly diagnosed metastatic EGFR+ NSCLC.